A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

NCT04830137 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Waldenstrom Macroglobulinemia (WM)
Mantle Cell Lymphoma (MCL)
Marginal Zone Lymphoma (MZL)
Follicular Lymphoma (FL)
Diffuse Large B-cell Lymphoma (DLBCL)
Primary Central Nervous System Lymphoma (PCNSL)

Interventions

DRUG: NX-2127

Sponsor

Nurix Therapeutics, Inc.